• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    President, R&D Krishnan Suma converted options into 67,225 shares and covered exercise/tax liability with 30,584 shares, increasing direct ownership by 1% to 1,428,155 units (SEC Form 4)

    3/3/26 6:33:07 PM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $KRYS alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Krishnan Suma

    (Last) (First) (Middle)
    C/O KRYSTAL BIOTECH, INC.
    2100 WHARTON STREET, SUITE 701

    (Street)
    PITTSBURGH PA 15203

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    Krystal Biotech, Inc. [ KRYS ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director X 10% Owner
    X Officer (give title below) Other (specify below)
    President, R&D
    3. Date of Earliest Transaction (Month/Day/Year)
    02/27/2026
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Common Stock 02/27/2026 M 22,500(1) A $0 1,436,211 D
    Common Stock 02/27/2026 F 10,236(2) D $275.64(3) 1,425,975 D
    Common Stock 02/27/2026 M 4,000(4) A $0 1,429,975 D
    Common Stock 02/27/2026 F 1,820(5) D $275.64(3) 1,428,155 D
    Common Stock 02/27/2026 M 8,750(6)(7) A $0 1,486,806 I By Spouse(8)
    Common Stock 02/27/2026 F 3,981(7)(9) D $275.64(3) 1,482,825 I By Spouse(8)
    Common Stock 02/27/2026 M 26,250(7)(10) A $0 1,509,075 I By Spouse(8)
    Common Stock 02/27/2026 F 11,942(7)(11) D $275.64(3) 1,497,133 I By Spouse(8)
    Common Stock 02/27/2026 M 5,725(7)(12) A $0 1,502,858 I By Spouse(8)
    Common Stock 02/27/2026 F 2,605(7)(13) D $275.64(3) 1,500,253 I By Spouse(8)
    Common Stock 90,000 I By SMK Trust
    Common Stock 50,000 I By Krishnan Family Trust(14)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Performance Stock Units (1) 02/27/2026 M 22,500 (1) (1) Common Stock 22,500 $0 0 D
    Restricted Stock Units (4) 02/27/2026 M 4,000 (4) (4) Common Stock 4,000 $0 12,000 D
    Stock Option (Right to Buy) $275.64 02/27/2026 A 18,100 (15) 02/26/2036 Common Stock 18,100 $0 18,100 D
    Restricted Stock Units (16) 02/27/2026 A 7,256 (17) (17) Common Stock 7,256 $0 7,256 D
    Performance Stock Units (18) 02/27/2026 A 43,536(19) (20) (21) Common Stock 43,536 $0 43,536 D
    Explanation of Responses:
    1. 45,000 performance stock units ("PSUs") were granted on February 29, 2024. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31, 2024, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and the remaining one-half of the PSUs granted, or 22,500 PSUs, vested on February 27, 2026.
    2. Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 22,500 PSUs on February 27, 2026.
    3. The closing price on February 27, 2026 of the Company's common stock on the Nasdaq Global Select Market.
    4. 16,000 restricted stock units ("RSUs") were granted on February 28, 2025. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period with the first installment, or 4,000 RSUs, vesting on February 27, 2026.
    5. Represents the number of shares of common stock surrendered to the Company for tax withholding upon the vesting of 4,000 RSUs on February 27, 2026.
    6. 35,000 restricted stock units ("RSUs") were granted on February 29, 2024, to the Reporting Person's spouse, Krish S. Krishnan. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's spouse continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period with the second installment, or 8,750 RSUs, vesting on February 27, 2026.
    7. These same shares are also being reported on a Form 4 by the Reporting Person's spouse, Krish S. Krishnan.
    8. Directly beneficially owned by Krish S. Krishnan, the spouse of the Reporting Person.
    9. Represents number of shares of common stock surrendered to the Company for tax withholding by the Reporting Person's spouse, Krish S. Krishnan, upon the vesting of 8,750 RSUs on February 27, 2026.
    10. 52,500 PSUs were granted on February 29, 2024, to the Reporting Person's spouse, Krish S. Krishnan. Each PSU represented a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the year ended December 31, 2024, as approved by the Company's Compensation Committee, and the Reporting Person's spouse continued service to the Company on each applicable vesting date following such achievement. The PSUs vested ratably over a two-year period. All of the performance criteria were achieved and the remaining one-half of the PSUs granted, or 26,250 PSUs, vested on February 27, 2026.
    11. Represents number of shares of common stock surrendered to the Company for tax withholding by the Reporting Person's spouse, Krish S. Krishnan, upon the vesting of 26,250 PSUs on February 27, 2026.
    12. 22,900 restricted stock units ("RSUs") were granted on February 28, 2025, to the Reporting Person's spouse, Krish S. Krishnan. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's spouse continued service to the Company on each applicable vesting date. The RSUs vest ratably over a four-year period with the first installment, or 5,725 RSUs, vesting on February 27, 2026.
    13. Represents number of shares of common stock surrendered to the Company for tax withholding by the Reporting Person's spouse, Krish S. Krishnan, upon the vesting of 5,725 RSUs on February 27, 2026.
    14. Directly beneficially owned by the Krishnan Family Trust. The reporting person and her spouse are each joint beneficial owners of the trust with joint voting and investment control.
    15. The stock options vest in four equal annual installments beginning on February 27, 2027.
    16. Each RSU represents a contingent right to receive one share of the Company's common stock, subject to the Reporting Person's continued service to the Company on each applicable vesting date.
    17. The RSUs vest in four equal annual installments with the first installment vesting on February 27, 2027.
    18. Each PSU represents a contingent right to receive one share of the Company's common stock, subject to the achievement of certain performance criteria during the three year performance period, as approved by the Company's Compensation Committee, and the Reporting Person's continued service to the Company on the vesting date.
    19. The number of PSUs in this column represents the number of shares of common stock the Reporting Person will receive assuming achievement of all of the performance criteria set by the Company's Compensation Committee for this PSU award and full vesting of this PSU award.
    20. If any applicable portion of the performance criteria have been achieved, the PSU award shall cliff vest on February 27, 2029.
    21. If some or all of the performance criteria are not achieved, the applicable portion of the PSU award will be forfeited.
    Remarks:
    /s/ Suma M. Krishnan 03/03/2026
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $KRYS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $KRYS

    DatePrice TargetRatingAnalyst
    3/27/2026Peer Perform
    Wolfe Research
    1/6/2026$309.00Neutral → Buy
    Citigroup
    3/5/2025$245.00Buy
    Jefferies
    8/6/2024$195.00 → $204.00Buy → Neutral
    Citigroup
    11/20/2023$160.00Buy
    Goldman
    10/24/2023$100.00Overweight
    Cantor Fitzgerald
    10/12/2023$160.00Buy
    Citigroup
    9/7/2023$154.00Buy
    Berenberg
    More analyst ratings

    $KRYS
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    May 19, 2023 - FDA Approves First Topical Gene Therapy for Treatment of Wounds in Patients with Dystrophic Epidermolysis Bullosa

    For Immediate Release: May 19, 2023 Today, the U.S. Food and Drug Administration approved Vyjuvek, a herpes-simplex virus type 1 (HSV-1) vector-based gene therapy, for the treatment of wounds in patients 6 months of age and older with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene.  “Vyjuvek is the first FDA-approved gene therapy treatment for DEB, a

    5/19/23 1:48:20 PM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KRYS
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP, General Counsel Thomas John Charles sold $193,903 worth of shares (642 units at $302.03) as part of a pre-agreed trading plan, closing all direct ownership in the company (SEC Form 4)

    4 - Krystal Biotech, Inc. (0001711279) (Issuer)

    5/27/26 5:17:56 PM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    New insider Goux Laurent Louis Jean claimed ownership of 919 shares (SEC Form 3)

    3 - Krystal Biotech, Inc. (0001711279) (Issuer)

    3/6/26 6:26:21 PM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    New insider Thomas John Charles claimed ownership of 642 shares (SEC Form 3)

    3 - Krystal Biotech, Inc. (0001711279) (Issuer)

    3/6/26 6:24:44 PM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KRYS
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wolfe Research initiated coverage on Krystal Biotech

    Wolfe Research initiated coverage of Krystal Biotech with a rating of Peer Perform

    3/27/26 8:50:59 AM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Krystal Biotech upgraded by Citigroup with a new price target

    Citigroup upgraded Krystal Biotech from Neutral to Buy and set a new price target of $309.00

    1/6/26 8:26:47 AM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Jefferies initiated coverage on Krystal Biotech with a new price target

    Jefferies initiated coverage of Krystal Biotech with a rating of Buy and set a new price target of $245.00

    3/5/25 7:35:58 AM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KRYS
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call

    NORWOOD, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, today announced that the Company's management team will host a conference call and webcast on Tuesday, May 26 at 8:00 a.m. EDT to discuss updated data for its Phase 1/2 study of CRB-701, a next-generation Nectin-4 antibody drug candidate (ADC), in both head and neck squamous cell carcinoma (HNSCC) as well as cervical cancer. The data, which will be presented at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, represent an April 1, 2026 data cut, and will include cli

    5/21/26 8:00:00 AM ET
    $CRBP
    $KRYS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

    VYJUVEK approved for the treatment of DEB from birth with flexible administration options similar to those already granted in the United States, European Union, and Japan  VYJUVEK is the first genetic medicine approved in the United Kingdom for the treatment of DEB PITTSBURGH, May 18, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) today announced that, on May 15, 2026, the United Kingdom Medicines and Healthcare products Regulatory Agency (MHRA) granted marketing authorization to VYJUVEK® (beremagene geperpavec-svdt) for the treatment of wounds in patients with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (CO

    5/18/26 8:00:00 AM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Krystal Biotech to Present at BofA Securities 2026 Health Care Conference

    PITTSBURGH, May 07, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) today announced that the Company will participate in the BofA Securities 2026 Health Care Conference on May 13, 2026, in Las Vegas. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 11:20 am PT and host investor meetings throughout the day. A webcast of the presentation will be available here beginning at 11:20 am PT on Wednesday, May 13, 2026 and will be posted on the Investors section of the Company's website. About Krystal Biotech, Inc.Krystal Biotech, Inc. (NASDAQ:KRYS) is a fully integrated, commercial-stage, global biotechnology comp

    5/7/26 8:00:00 AM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KRYS
    SEC Filings

    View All

    SEC Form 144 filed by Krystal Biotech Inc.

    144 - Krystal Biotech, Inc. (0001711279) (Subject)

    6/4/26 4:30:59 PM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 144 filed by Krystal Biotech Inc.

    144 - Krystal Biotech, Inc. (0001711279) (Subject)

    6/4/26 4:30:46 PM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Krystal Biotech Inc.

    SCHEDULE 13G/A - Krystal Biotech, Inc. (0001711279) (Subject)

    5/4/26 7:10:31 AM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KRYS
    Leadership Updates

    Live Leadership Updates

    View All

    Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice President of Market Access and Patient Services

    Ms. McDonough previously served as Senior Vice President of Patient Access, Analytics, and Operations at Krystal Biotech (NASDAQ:KRYS), where she helped lead the U.S. launch of VYJUVEK®, supporting its growth from FDA approval in 2023 to $389 million in annual sales in 2025 Ms. McDonough to lead Palvella's Market Access and Patient Services organizations, advancing payer engagement, patient support, specialty distribution, and access strategy for the Company's QTORIN™ programs targeting serious, rare skin diseases and vascular malformations WAYNE, Pa., March 23, 2026 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc. (Palvella or "the Company") (Nasdaq: PVLA), a clinical-stage biopharmaceut

    3/23/26 7:30:00 AM ET
    $KRYS
    $PVLA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    Jeune Aesthetics Appoints Marc Forth as Chief Executive Officer

    PITTSBURGH, April 07, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. ("Jeune"), a wholly owned subsidiary of Krystal Biotech, Inc. ("Krystal") (NASDAQ:KRYS) leveraging Krystal's clinically validated gene-delivery platform to fundamentally address and reverse the biology of aging skin, announced today the appointment of Marc Forth as Chief Executive Officer (CEO), effective today. A veteran of the healthcare industry, Mr. Forth has over 30 years of commercial and executive leadership experience, with an extensive track record of building innovative companies as well as launching and commercializing leading brands, including BOTOX®, one of the most widely recognized global brands. Mr. Forth

    4/7/25 4:30:00 PM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Jeune Aesthetics Appoints Nishant Saxena as Chief Financial Officer

    PITTSBURGH, Jan. 14, 2025 (GLOBE NEWSWIRE) -- Jeune Aesthetics, Inc. ("Jeune"), a wholly owned subsidiary of Krystal Biotech, Inc. ("Krystal") (NASDAQ:KRYS) leveraging Krystal's clinically validated gene-delivery platform to fundamentally address and reverse the biology of aging skin, announced today the appointment of Nishant Saxena as Chief Financial Officer (CFO), effective January 15, 2025. Mr. Saxena has over 20 years of experience in finance, strategy, capital markets, mergers and acquisitions, and corporate development. Most recently, he was a Managing Director in Evercore's healthcare group, where he advised on transactions totaling over $500 billion in aggregate value. "It is my

    1/14/25 8:00:00 AM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KRYS
    Financials

    Live finance-specific insights

    View All

    Corbus Pharmaceuticals Announces the Appointment of Nishant Saxena as Chief Business Officer and Schedules a Pre-2026 ASCO CRB-701 Data Conference Call

    NORWOOD, Mass., May 21, 2026 (GLOBE NEWSWIRE) -- Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP), a clinical-stage company focused on developing promising new therapies in oncology and obesity, today announced that the Company's management team will host a conference call and webcast on Tuesday, May 26 at 8:00 a.m. EDT to discuss updated data for its Phase 1/2 study of CRB-701, a next-generation Nectin-4 antibody drug candidate (ADC), in both head and neck squamous cell carcinoma (HNSCC) as well as cervical cancer. The data, which will be presented at the upcoming 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, represent an April 1, 2026 data cut, and will include cli

    5/21/26 8:00:00 AM ET
    $CRBP
    $KRYS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Krystal Biotech Announces First Quarter 2026 Financial and Operating Results

    $116.4 million in 1Q VYJUVEK global revenue and $846.7 million since launch Enrollment complete in KB803 (corneal abrasions in DEB patients) registrational study On track for KB803 and KB801 (NK) registrational data readouts in 2026 FDA grants platform technology designation for KB407 (CF) and KB111 (HHD) Strong balance sheet, ending the quarter with $1.0 billion in cash and investments PITTSBURGH, May 04, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) today reported financial results for the first quarter ending March 31, 2026 and provided a business update. "Following a successful 2025, we are entering 2026 with strong momentum, including two potential

    5/4/26 7:00:00 AM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Krystal Biotech to Report First Quarter 2026 Financial Results on May 4, 2026

    PITTSBURGH, April 21, 2026 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the "Company") (NASDAQ:KRYS) announced today that it will report its first quarter 2026 financial results on Monday, May 4, 2026, prior to the open of U.S. markets. The Company's management will also host a conference call and webcast at 8:30 am ET on Monday, May 4, 2026, to discuss the financial results and provide a business update. Investors and the general public can access the live webcast at: https://www.webcaster5.com/Webcast/Page/3018/53916. For those unable to listen to the live webcast, a replay will be available for at least 30 days on the Investors section of the Company's website at www.krystalbio.com. A

    4/21/26 8:00:00 AM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $KRYS
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Krystal Biotech Inc.

    SC 13G/A - Krystal Biotech, Inc. (0001711279) (Subject)

    11/14/24 9:00:58 PM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    Amendment: SEC Form SC 13G/A filed by Krystal Biotech Inc.

    SC 13G/A - Krystal Biotech, Inc. (0001711279) (Subject)

    11/12/24 10:32:12 AM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed by Krystal Biotech Inc.

    SC 13G - Krystal Biotech, Inc. (0001711279) (Subject)

    10/16/24 12:28:49 PM ET
    $KRYS
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care